Clinical Trial Update: Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing namilumab versus adalimumab in patients with moderate-to-severe early rheumatoid arthritis inadequately responding to metho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Namilumab (namilumab)

Snippet

Sponsor: Takeda | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2019-02-05